Sugi Predict

Sugi Predict / Compounds / SCHEMBL20883229

SCHEMBL20883229

SCHEMBL20883229

[N-]=[N+]=NCCOCCOCCNC(=O)CCC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 3/20 0.39
▸ CA12 O43570 4/20 0.37
▸ CA1 P00915 4/20 0.37
▸ CA2 P00918 4/20 0.37
▸ CA4 P22748 4/20 0.37
▸ CA9 Q16790 4/20 0.37
▸ CA14 Q9ULX7 4/20 0.37
▸ EPOR P19235 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TTR P02766 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ KDM5C P41229 2/20 0.32
▸ PHF8 Q9UPP1 2/20 0.32
▸ KDM2A Q9Y2K7 2/20 0.32
▸ KDM6B O15054 1/20 0.32
▸ FOLH1 Q04609 1/20 0.32
▸ EGLN1 Q9GZT9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23157517 1.00 CRBN (0.39) CRBNCA12CA1CA2CA4
SCHEMBL23157563 1.00 CRBN (0.39) CRBNCA12CA1CA2CA4
SCHEMBL20552921 1.00 CRBN (0.39) CRBNCA12CA1CA2CA4
SCHEMBL26617637 0.98 CRBN (0.37) CRBNCA12CA1CA2CA4
SCHEMBL17282361 0.94 CRBN (0.41) CRBNCA12CA1CA2CA4
SCHEMBL18886281 0.94 CRBN (0.41) CRBNCA12CA1CA2CA4
SCHEMBL23158184 0.93 CRBN (0.38) CRBNCA12CA1CA2CA4
SCHEMBL25495673 0.93 CRBN (0.38) CRBNCA12CA1CA2CA4
SCHEMBL23157890 0.91 CRBN (0.37) CRBNEPORTTRKDM4E
SCHEMBL23157910 0.91 CRBN (0.37) CRBNEPORTTRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120037399-A Programmable polymeric drugs 索尼集团公司 2025-05-27 — — CN disclosed
US-20240207423-A1 PROGAMMABLE POLYMERIC DRUGS SONY GROUP CORP (JP) 2024-06-27 — — US disclosed
US-20240207423-A1 PROGAMMABLE POLYMERIC DRUGS SONY GROUP CORP (JP) 2024-06-27 — — US disclosed
EP-3737418-B1 POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS SONY GROUP CORP (JP) 2024-02-28 — — EP disclosed
US-20230031576-A1 RADIOLABELLED TARGETING LIGANDS Clarity Pharmaceuticals Ltd (AU) 2023-02-02 — — US disclosed
US-20220168433-A1 PROGRAMMABLE POLYMERIC DRUGS Sony Group Corporation (JP) 2022-06-02 — — US disclosed
US-20220168433-A1 PROGRAMMABLE POLYMERIC DRUGS Sony Group Corporation (JP) 2022-06-02 — — US disclosed
US-20220168435-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2022-06-02 — — US disclosed
US-20220160887-A1 PROGRAMMABLE POLYMERIC DRUGS Sony Group Corporation (JP) 2022-05-26 — — US disclosed
CN-114430738-A Programmable polymeric pharmaceuticals 索尼集团公司 2022-05-03 — — CN disclosed
US-20200353094-A1 PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS Sony Group Corporation (JP) 2020-11-12 — — US disclosed
WO-2020210689-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
WO-2020210692-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
WO-2020210694-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
WO-2020210694-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
WO-2020210692-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
WO-2020210689-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
US-20200222554-A1 PROGRAMMABLE DENDRITIC DRUGS Sony Group Corporation (JP) 2020-07-16 — — US disclosed
WO-2019118714-A1 IONIC POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS SONY CORPORATION (JP) 2019-06-20 — — WO disclosed
WO-2019071208-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2019-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200353094-A1 PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS PARP1, PARP11, PHOSPHO1 CRBN 2184/4885CA12 4675/4885CA1 4373/4885
US-20220160887-A1 PROGRAMMABLE POLYMERIC DRUGS CHRM1, NCL, PBRM1 CRBN 227/4885CA12 2584/4885CA1 1348/4885
US-20220168433-A1 PROGRAMMABLE POLYMERIC DRUGS CHRM1, PBRM1, CHRM2 CRBN 312/4885CA12 2163/4885CA1 1378/4885
US-20240207423-A1 PROGAMMABLE POLYMERIC DRUGS OPRM1, CHRM1, TUBB3 CRBN 2190/4885CA12 2267/4885CA1 1154/4885
US-20220168435-A1 PROGRAMMABLE POLYMERIC DRUGS CHRM1, PBRM1, CHRM2 CRBN 313/4885CA12 2169/4885CA1 1380/4885
US-20200222554-A1 PROGRAMMABLE DENDRITIC DRUGS CHRM1, TLL1, TEX264 CRBN 1730/4885CA12 4507/4885CA1 2402/4885
US-20230031576-A1 RADIOLABELLED TARGETING LIGANDS FOLH1, CXCR3, ACKR3 CRBN 2035/4885CA12 118/4885CA1 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.